Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost-effectiveness Analysis

被引:9
作者
Twiner, Michael J. [1 ]
Marinica, Alexander L. [7 ]
Kuper, Kenneth [8 ]
Goodman, Allen [2 ]
Mahn, James J. [3 ]
Burla, Michael J. [1 ,11 ]
Brody, Aaron M. [1 ]
Carroll, Justin A. [3 ,12 ]
Willock, Robina Josiah [9 ]
Flack, John M. [4 ,5 ,6 ]
Nasser, Samar A. [10 ]
Levy, Phillip D. [6 ]
机构
[1] Wayne State Univ, Dept Emergency Med, Detroit, MI USA
[2] Wayne State Univ, Dept Econ, Detroit, MI USA
[3] Wayne State Univ, Sch Med, Detroit, MI USA
[4] Wayne State Univ, Div Transit Res & Clin Epidemiol, Detroit, MI USA
[5] Wayne State Univ, Dept Med, Detroit, MI 48202 USA
[6] Wayne State Univ, Cardiovasc Res Inst, Detroit, MI 48202 USA
[7] Sinai Grace Hosp, Dept Surg, Detroit, MI USA
[8] St Johns Hosp, Dept Emergency Med, Detroit, MI USA
[9] Morehouse Sch Med, Community Hlth & Prevent Med, Atlanta, GA 30310 USA
[10] Univ Michigan, Coll Educ Hlth & Human Serv, Dearborn, MI 48128 USA
[11] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA
[12] Ohio State Univ, Dept Emergency Med, Coll Med, Columbus, OH 43210 USA
关键词
LEFT-VENTRICULAR HYPERTROPHY; UNITED-STATES ADULTS; SYSTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE; AFRICAN-AMERICANS; HEALTH-STATUS; PREVALENCE; FAILURE; AWARENESS; PREVENTION;
D O I
10.1111/acem.13122
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
ObjectivesPoorly controlled hypertension (HTN) is extremely prevalent and, if left unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to conditions such as heart failure. To address this, we designed a multidisciplinary program to detect and treat SHHD in a high-risk, predominantly African American community. The primary objective of this study was to determine the cost-effectiveness of our program. MethodsStudy costs associated with identifying and treating patients with SHHD were calculated and a sensitivity analysis was performed comparing the effect of four parameters on cost estimates. These included prevalence of disease, effectiveness of treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH], or blood pressure [BP] control as separate measures), echocardiogram costs, and participant time/travel costs. The parent study for this analysis was a single-center, randomized controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients (94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were randomized, with 88 (72%) completing the study. Patients were clinically evaluated and medically managed over the course of 1 year with repeated echocardiograms. Costs of these interventions were analyzed and, following standard practices, a cost per quality-adjusted life-year (QALY) less than $50,000 was defined as cost-effective. ResultsTotal costs estimates for the program ranged from $117,044 to $119,319. Cost per QALY was dependent on SHHD prevalence and the measure of effectiveness but not input costs. Cost-effectiveness (cost per QALY less than $50,000) was achieved when SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, and 2.9% for achievement of BP control. ConclusionsIn this cohort of predominantly African American patients with uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost-effective across a range of assumptions. These data suggest that multidisciplinary programs such as this can be a cost-effective mechanism to mitigate the cardiovascular consequences of HTN in emergency department patients with uncontrolled BP.
引用
收藏
页码:168 / 176
页数:9
相关论文
共 50 条
  • [21] Cost-effectiveness of obstructive sleep apnea screening for patients with diabetes or chronic kidney disease
    Okubo, Reiko
    Kondo, Masahide
    Hoshi, Shu-ling
    Yamagata, Kunihiro
    SLEEP AND BREATHING, 2015, 19 (03) : 1081 - 1092
  • [22] Pulse oximetry as a screening test for congenital heart defects in newborn infants: a cost-effectiveness analysis
    Roberts, T. E.
    Barton, P. M.
    Auguste, P. E.
    Middleton, L. J.
    Furmston, A. T.
    Ewer, A. K.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2012, 97 (03) : 221 - 226
  • [23] Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information
    Mohseninejad, Leyla
    Feenstra, Talitha
    van der Horst, Henriette E.
    Woutersen-Koch, Helen
    Buskens, Erik
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (06) : 947 - 957
  • [24] Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer's disease in Brazil
    da Silva, Luciana R.
    Vianna, Cid M. M.
    Mosegui, Gabriela B. G.
    Peregrino, Antonio A. F.
    Marinho, Valeska
    Laks, Jerson
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (03) : 218 - 224
  • [25] Cost-effectiveness analysis of cardiovascular risk factor screening in women who experienced hypertensive pregnancy disorders at term
    van Baaren, Gert-Jan
    Hermes, Wietske
    Franx, Arie
    van Pampus, Maria G.
    Bloemenkamp, Kitty W. M.
    van der Post, Joris A.
    Porath, Martina
    Ponjee, Gabrielle A. E.
    Tamsma, Jouke T.
    Mol, Ben Willem J.
    Opmeer, Brent C.
    de Groot, Christianne J. M.
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2014, 4 (04) : 264 - 270
  • [26] Cost-effectiveness of Intensive vs Standard Blood Pressure Control Among Older Patients With Hypertension
    Liao, Chia-Te
    Toh, Han Siong
    Sun, Li
    Yang, Chun-Ting
    Hu, Angie
    Wei, Dongmei
    Melgarejo, Jesus
    Zhang, Zhen-Yu
    JAMA NETWORK OPEN, 2023, 6 (02)
  • [27] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Gregoire, Jean
    Champsi, Salimah
    Jobin, Manon
    Martinez, Laura
    Urbich, Michael
    Rogoza, Raina M.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3262 - 3279
  • [28] Screening, prevention and treatment of cervical cancer-A global and regional generalized cost-effectiveness analysis
    Ginsberg, Gary Michael
    Edejer, Tessa Tan-Torres
    Lauer, Jeremy A.
    Sepulveda, Cecilia
    VACCINE, 2009, 27 (43) : 6060 - 6079
  • [29] Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China
    Huang, Yun
    Zhou, Hua
    Fang, Chongbo
    Ma, Lili
    Zhang, Yuyu
    Rong, Weibo
    Liu, Xiaoli
    Ye, Honghua
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2024, 83 (01) : 86 - 92
  • [30] Cost-Effectiveness of HIV Screening in STD Clinics, Emergency Departments, and Inpatient Units: A Model-Based Analysis
    Prabhu, Vimalanand S.
    Farnham, Paul G.
    Hutchinson, Angela B.
    Soorapanth, Sada
    Heffelfinger, James D.
    Golden, Matthew R.
    Brooks, John T.
    Rimland, David
    Sansom, Stephanie L.
    PLOS ONE, 2011, 6 (05):